Effects of iron deprivation on Mycobacterium avium growth

Tubercle and Lung Disease

Volumn 79, Issue 5, 1999, Pages 321-328

  Gomes, M S ^b   Dom, G ^b   Pedrosa, J ^b   Boelaert, J R ^a   Appelberg, R ^b  

^a General Hospital St Jan   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 3 (2 BIPYRIDYL)ISOQUINOLINE DERIVATIVE; ACETOACETIC ACID; DEFEROXAMINE; GAMMA INTERFERON; IRON; ISOQUINOLINE DERIVATIVE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; UNCLASSIFIED DRUG; VUF 8514;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BONE MARROW; CONTROLLED STUDY; CULTURE MEDIUM; INTRAPERITONEAL DRUG ADMINISTRATION; IRON DEFICIENCY; MACROPHAGE; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

MYCOBACTERIUM AVIUM;

EID: 0032860952     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1054/tuld.1999.0216     Document Type: Article

References (27)

1. Barclay R, Ratledge C. Iron-binding compounds of Mycobacterium avium, M. intracellulare, M. scrofulaceum and mycobactin-dependent M. paratuberculosis and M. avium. J Bacteriol. 153:1983;1138-1146.
2. Wong D K, Gobin J, Horwitz M A, Gibson B W. Characterization of exochelin of Mycobacterium avium: evidence for saturated and unsaturated and for acid and ester forms. J Bacteriol. 178:1996;6394-6398.
3. Gobin J, Horwitz M A. Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med. 183:1996;1527-1532.
4. Dhople A, Ibanez M A, Poirier T C. Role of iron in the pathogenesis of Mycobacterium avium infection in mice. Microbios. 87:1996;77-87.
5. Douvas G S, May M H, Crowle A J. Transferrin, iron and serum lipids enhance or inhibit Mycobacterium avium replication in human macrophages. J Infect Dis. 167:1993;857-864.
6. Gomes M S, Appelberg R. Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance againstMycobacterium avium. Immunology. 95:1998;165-168.
7. Boelaert J R, Weinberg G A, Weinberg E D. Altered iron metabolism in HIV infection: mechanisms, possible consequences and proposals for management. Infect Agent Dis. 5:1996;36-46.
8. Al-Khafaji B, Kralovic S, Smith R D. Increased hepatic iron in the acquired immunodeficiency syndrome: an autopsy study. Modern Pathology. 10:1997;474-480.
9. Brittenham G M. Development of iron chelating agents for clinical use. Blood. 80:1992;569-574.
10. Bergeron R J, Wiegand J, Brittenham G M. HBED: a potential alternative to desferrioxamine for iron-chelating therapy. Blood. 91:1998;1446-1452.
11. Lambrecht, R, S, Mjanger, A, K, Iron availability alters extracellular and intracellular replication of Mycobacterium avium. [Abstracts of the Annual Meeting of American Society for Microbiology, Washington DC, abstr nr U-70], 1993.
12. Dhople A M, Dhople A A, Ibanez M A. In vitro activity of 2,2′-bipyridyl analogues against Mycobacterium avium and Mycobacterium tuberculosis. Tuber Lung Dis. 76:1995;136-140.
13. Newman S L, Gootee L, Stroobant V, van der Goot H, Boelaert J R. Inhibition of growth of Histoplasma capsulatum yeast cells in human macrophages by the iron chelator VUF 8514 and comparison of VUF 8514 with desferrioxamine. Antimicrob Agents Chemother. 39:1995;1824-1829.
14. Appelberg R, Orme I M. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology. 80:1993;352-359.
15. Byrd T, Horwitz M A. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest. 83:1989;1457-1465.
16. Schneider Y-J. Optimization of hybridoma cell growth and of monoclonal antibody secretion in a chemically defined serum and protein-free culture medium. J Immunol Methods. 116:1989;65-77.
17. Wallace R S, Nash D R, Steele L C, Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol. 24:1986;976-981.
18. Yajko D M, Nassos P S, Hadley W K. Broth microdilution testing of susceptibility to 30 antimicrobial agents of Mycobacterium avium strains from patients with AIDS. Antimicrob Agents Chemother. 31:1987;1579-1584.
19. Stewart C C. Murine mononuclear phagocytes from Bone Marrow. Adams D O, Edelson P J, Koren H. Methods for Studying Mononuclear Phagocytes. 1981;5-20 Academic Press, New York.
20. Weinberg G A. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 38:1994;997-1003.
21. Boelaert J R, de Locht M, Van Cutsem J. Desferrioxamine: its effects on the growth of microorganisms in vitro and in experimental infections. Rev Med Microbiol. 4:1993;171-175.
22. Gordeuk V R, Thuma P, Brittenham G. Effects of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New England J Med. 327:1992;1473-1477.
23. De Zwart M A H, van der Goot H, Timmerman H. Synthesis of copper-dependent antimycoplasmal activity of l-amino-3-(2-pyridyl) isoquinoline derivatives.2.Amidines. J Med Chem. 32:1989;487-493.
24. De Brauwer E, Van Landuyt H W, Gordts B, Boelaert J R. In vitro acquisition of iron from the iron-desferrioxamine complex by Aeromonas hydrophila. Clin Microbiol Infection. 1:1996;273-274.
25. Steward A W I, Madigan T, Bretnall A, Hassan I F. An improved animal model for studying desferrioxamine. Brit J Haematol. 95:1996;654-659.
26. Gordeuk V R, McLaren G D, Samowitz W. Etiologies, consequences, and treatment of iron overload. Crit Rev Clin Lab Sci. 31:1994;89-133.
27. Weinberg E. Iron and Infection. Microbiol Rev. 42:1978;45-66.